Microtide Biotechnology

Microtide Biotechnology (微滔生物) is a Shanghai-based biotech company founded on June 25, 2025, spun out from Beijing Shali Biotech's in vivo CAR-T platform . The company develops innovative in vivo CAR-T cell therapies, with its core candidate GT801 targeting both blood cancers and autoimmune diseases . Yarong Liu serves as founder and CEO, and as of mid-2026 also chairs the board .

The company has moved quickly through financing: it raised over RMB 100 million in an angel round led by Qiming Venture Partners in late 2025, with B Capital, Xingze Capital, and Shunxi Fund co-investing , then closed over $50 million in combined Series A and A+ rounds by May 2026, with Qiming following on . The fresh capital is earmarked for GT801's clinical trials, regulatory filings, and global expansion of its in vivo CAR-T pipeline .